CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 262 enrolled
Drug / intervention
LY2189265 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00630825
NCT00630825Phase 2Completed
CompareCT.gov

The Effect of Dose Titration of LY2189265 in Overweight and Obese Patients With Type 2 Diabetes Mellitus

Eli Lilly and Company·interventional·Posted Mar 7, 2008·Updated Dec 10, 2014

In Brief

A Phase 2 clinical trial evaluating LY2189265 and Placebo for Diabetes Mellitus Type 2. Completed, enrolled 262 participants across 34 sites in 2 countries.

Detailed Summary

To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus Type 2
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 7, 2008
Enrollment StartApr 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.3 years ago

Interventions

LY2189265drug

Placebodrug